Abstract Number: 1515 • ACR Convergence 2020
Renal Responder Status and Associated Clinical Variables in the Lupus Accelerating Medicines Partnership Cohort
Background/Purpose: Poor therapeutic response rates contribute to the increased morbidity and mortality associated with lupus nephritis. Early identification of patients likely to respond is crucial…Abstract Number: 1516 • ACR Convergence 2020
The Value of Renal Biopsy at Lower Levels of Proteinuria in Patients Enrolled in the Lupus Accelerating Medicines Partnership
Background/Purpose: Lupus nephritis continues to be the complication with the highest standardized mortality ratio in Systemic Lupus Erythematosus (SLE), and a late diagnosis associates with…Abstract Number: 1645 • ACR Convergence 2020
Placebo Group Responses in Clinical Trials of Patients with Osteoarthritis: Data from the Tanezumab Development Program
Background/Purpose: The level of placebo group response in clinical trials for chronic pain conditions is a concern for the development of novel analgesics1. Here, we…Abstract Number: 1893 • ACR Convergence 2020
Predictors of Response in Secukinumab-treated Patients with Ankylosing Spondylitis: Logistic Regression and Machine Learning Analyses
Background/Purpose: Predicting outcomes early in the disease course in patients (pts) with ankylosing spondylitis (AS) is challenging, owing to heterogeneity of symptoms, varying disease severity,…Abstract Number: 2031 • ACR Convergence 2020
Which Disease Activity Outcome Measure Discriminates Best in Axial Spondyloarthritis? A Systematic Literature Review and Meta-analysis
Background/Purpose: Several disease activity response and status criteria are used to assess treatment efficacy in RCTs in axial spondyloarthritis (axSpA). Response criteria include: the Assessment…